Get the Stockscreener App
1.17
0.00%
0.00
Cardiol Therapeutics Inc stock is traded at $1.17, with a volume of 1.35M.
It is up +0.00% in the last 24 hours and down -16.43% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.17
Open:
$1.14
24h Volume:
1.35M
Relative Volume:
2.39
Market Cap:
$97.94M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-3.523
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
-10.69%
1M Performance:
-16.43%
6M Performance:
-2.50%
1Y Performance:
-42.36%
1-Day Range:
$1.1335
$1.20
1-Week Range:
$1.10
$1.345
52-Week Range:
$0.7709
$2.63
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.17 | 100.83M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Cardiol Therapeutics Inc. Ranks High in Smart Money Tracker2025 Buyback Activity & Free Community Consensus Stock Picks - mustnews.co.kr
Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses - MSN
Cardiol rises on database lockup for acute myocarditis therapy trial - MSN
Cardiol Therapeutics Inc. shares fall 1.64% after-hours as stock futures decline ahead of Trump's Ukraine meeting. - AInvest
A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics - thedeepdive.ca
Why is Cardiol Therapeutics Inc. stock going downTrade Exit Report & Expert Approved Momentum Ideas - thegnnews.com
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cardiol Therapeutics shares rise 1.49% premarket after BioCardia and CART-Tech announce exclusive development and commercialization agreement for Heart3D Fusion Imaging. - AInvest
Cardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx - TipRanks
The Significance of Moving Averages in Cardiol Therapeutics Inc Inc. (CRDL) Price Performance - investchronicle.com
Healthcare Analysts Bullish on SI-Bone, Delcath Systems, and Cardiol Therapeutics - AInvest
Chart based analysis of Cardiol Therapeutics Inc. trendsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - Newser
What technical models suggest about Cardiol Therapeutics Inc.’s comebackPortfolio Risk Summary & Entry and Exit Point Strategies - Newser
How to integrate Cardiol Therapeutics Inc. into portfolio analysis toolsJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
Relief Rally in Cardiol Therapeutics Inc. Stock — Can It Hold [Insider Selling]Low Drawdown Trading Strategies - 선데이타임즈
Will Cardiol Therapeutics Inc. stock go up soon [2025 Trading Volume Trends]Free Community Trade Idea Sharing Platform - Newser
Analyzing Cardiol Therapeutics Inc. with multi timeframe chartsAI-Based Stock Behavior Forecast Engine - Newser
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH) - TradingView
Analyzing drawdowns of Cardiol Therapeutics Inc. with statistical toolsWeekly Growth Portfolio Performance Summary - Newser
Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada - streetwisereports.com
Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment - streetwisereports.com
Biotech Announces Topline Results From Cardiovascular Drug Trial - streetwisereports.com
Cardiol Therapeutics to Participate in Fireside Chat at Canaccor - GuruFocus
Cardiol Therapeutics to Present at Canaccord Genuity Conference - TipRanks
Fluor Acknowledges Court Decision on Santos’ Gladstone LNG Project - The Globe and Mail
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference - Newsfile
Cardiol Therapeutics Reveals Latest Heart Disease Treatment Progress at Major Growth Conference - Stock Titan
Moving Average Trends for Cardiol Therapeutics Inc. Stock: What They IndicateEntry Confirmation Based on Volatility Analysis - Newser
Canadian Pharma Finds Promising Cardiovascular Breakthrough - streetwisereports.com
Watch for Trend Continuation in Cardiol Therapeutics Inc. Next WeekPortfolio Diversification Stock Ideas From Experts - beatles.ru
Cardiol Therapeutics (CRDL) Expected to Announce Earnings on Monday - Defense World
(CRDL) Risk-Controlled Trading Report (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics CRDL 2025Q2 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Cardiol Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Is Cardiol Therapeutics a buy? - Cantech Letter
Cardiol Therapeutics’ stock down 20% on Phase II CardiolRx failure - Yahoo Finance
Cardiol Therapeutics Announces US Listing - thedeepdive.ca
Cardiol Therapeutics shares rise 7.48% premarket after positive ARCHER trial results for CardiolRx™. - AInvest
Cardiol falls after mid-stage data for heart disease treatment - MSN
Roth bullish on Cardiol, says trial results enough to attract larger partner - TipRanks
Quantum Biopharma Ltd. shares rise 1.19% after-hours following Cardiol Therapeutics' positive ARCHER trial results. - AInvest
Cardiol data readout positive and not priced in, says H.C. Wainwright - TipRanks
Cardiol Therapeutics’ Cannabidiol Formulation Reduced Inflammation—Phase II Topline Data Ignites the Race to Treat Acute Myocarditis - InvestorNews
Cardiol ARCHER study not statistically significant, says Canaccord - TipRanks
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Barchart.com
Cardiol Therapeutics Reports Promising Phase II Trial Results for CardiolRx™ in Acute Myocarditis - TipRanks
Cardiol falls after mid-stage data for heart disease drug - Seeking Alpha
Cardiol Therapeutics Announces Topline Results from the Phase II - GuruFocus
(CRDL) Trading Report (CRDL:CA) - news.stocktradersdaily.com
Optimistic Buy Rating for Cardiol Therapeutics Amid Promising Clinical Trial Results and Strategic Advancements - TipRanks
Cardiol Therapeutics shares rise 2.73% intraday after Windtree announces Istaroxime Phase 2 interim analysis. - AInvest
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):